VALIDATION OF THE QUANTITATION METHODS OF 1-(β-PHENYLETHYL)-4-AMINO-1,2,4- TRIAZOLE BROMIDE SUBSTANCE BY SPECTROPHOTOMETRIC METHOD
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i2.22740Keywords:
Arterial hypertension, Spectrophotometry, Quantitation, Validation, Nil, 2, 4-triazole bromideAbstract
 Objective: The aim of the work was to determine the validation characteristics for the developed method of quantitation of 1-(β-phenylethyl)-4- amino-1,2,4-triazole bromide substance by absorption spectrophotometry in the ultraviolet region (UV).
Methods: For study purposes, the 1-(β-phenylethyl)-4-amino-1,2,4-triazole bromide substance and the standard sample, obtained by the state enterprise plant of chemical reagents†of scientific and technological complex institute of single crystals†of the National Academy of Sciences of Ukraine, was used. In the course of our work, we used chemical, physical, physicochemical (absorption spectrophotometry in the UV region), and statistical methods of analysis. The study was carried out at the Laboratory for Standardization and Technology of Medicines at the Department of Pharmaceutical Chemistry at Zaporizhzhia State Medical University (Ukraine).
Results: In the previous studies, we have developed a technique for spectrophotometric determination of the quantitative content of 1-(β-phenylethyl)- 4-amino-1,2,4-triazole bromide substance. The results of the studies showed that the absorption curve in the UV region of the substance solution has three absorption maxima, namely: λ1=252 nm, λ2=258 nm, and λ3=263 nm. To quantify the substance, the wavelength λ2=258 nm was used. The results of the quantitation of the 1-(β-phenylethyl)-4-amino-1,2,4-triazole bromide substance by spectrophotometric method prove that the technique developed by us is accurate and reproducible and meets the current requirements. To the developed methodology to ensure accurate and accurate analysis results, its validation was carried out. According to the requirements of the State Pharmacopoeia of Ukraine (2 editions), the developed method for quantitation of the substance was checked for such validation characteristics as specificity, linearity, range of application, accuracy, correctness, and robustness.
Conclusions: As a result of the work, it was proved that the method of quantitation of 1-(β-phenylethyl)-4-amino-1,2,4-triazolе bromide substance by spectrophotometric method is valid.
Downloads
References
Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: A meta-analysis of individual patient data. Lancet 2014;384:591-8.
White W. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutscs. N. Jersey: Humana Press; 2001.
Mazur I, Chekman I, Belenichev I. Metabolithotropic Drugs. Ukraine: Zaporozhye; 2007.
Belenichev I, Kucherenko L, Nagorna O, Yu V, Mazur I, Parnyuk N. Metabolite tropic mechanisms of cardioprotective effect of new antianginal and antihypertensive drug Hуpertril†in experimental ischemia of myocardium. Odessa Med J 2014;6(146):22-6.
Belenichev I, Volchek YU, Kucherenko L, Nagornaya E, Parnyuk N. Research activity ß-adrenoceptor blocking in the series of 1-alkyl (carboxyalkyl)-4-ylideneamino-1,2,4-triazole. Exp Clin Physiol Biochem 2014;3:24-32.
Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines. State Pharmacopoeia of Ukraine. 2nd ed., Vol. 1. Kharkiv: Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines, Ukrainian;2015. p. 85-100.
Beckett AH, Stenlake JB. UV-Visible Spectrophotometry: Practical Pharmaceutical Chemistry. 4th ed., Vol. 2. New Delhi: C.B.S. Publishers; 2001. p. 285-97.
Kucherenko L. On the standardization of hypertril substance. Pharm Rev 2015;2:64-7.
Manjunath S, Chouhan V, Sandeep S. Spectrophotometric estimation of levosulpiride in bulk drug and formulations. Int J Pharm Pharm Sci 2011;3:135-7.
Nayak SC, Kulkarni PV, Bhaskar V, Chavhan V. Development and validation of UV spectrophotometric method for simultaneous estimation of doxylamine succinate and pyridoxine hydrochloride in bulk and tablet dosage form. Int J Pharm Pharm Sci 2013;5:390-3.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.